With FDA filing for key gene therapy pushed back 6 months, uniQure opens the pocketbook to refresh the pipeline

UniQure will spend $55 million upfront with the potential for nearly $240 million in downstream milestones for shareholders to acquire EU biotech Corlieve Therapeutics and its lead gene therapy, dubbed AMT-260, for temporal lobe epilepsy, the partners said Tuesday.